Gastric cancer is biologically heterogeneous, and outcomes improve when treatment is chosen by tumor biology rather than by stage alone. A 98-gene testing panel gives oncology teams a population-level view of which patients are most likely to respond to HER2, anti-angiogenic, or immune-based regimens. For B2B buyers supplying hospitals and labs, the value of this assay is its ability to split a mixed gastric cancer population into actionable subgroups before therapy begins. In practice, a single histology report cannot predict which gastric tumor will answer to a given pathway, so genomic stratification has become routine in reference centers that manage advanced disease.
The panel combines next-generation sequencing of 98 cancer-relevant genes with microsatellite instability (MSI) and copy-number analysis. Formalin-fixed tumor tissue is extracted, libraries are prepared, and variants are called against a clinical-grade reference. Reportable alterations include HER2 amplification, FGFR2 changes, Claudin 18.2 status, and mismatch-repair deficiency. Each finding is mapped to a therapy or trial option so the clinician receives a decision-ready summary instead of a raw variant list. Bioinformatics annotation follows a curated knowledge base, and ambiguous variants are classified as pathogenic, likely pathogenic, or variant of unknown significance using published guidelines, which keeps reporting defensible.
This testing fits advanced or metastatic gastric and gastro-esophageal junction adenocarcinoma where a targeted or immunotherapy pathway is under consideration. It is most useful for patients who have not yet received a biomarker-directed line, and for cases where standard histology does not explain treatment resistance. Pathology teams also use it to confirm MSI-high status ahead of immune checkpoint therapy, and it supports enrollment into biomarker-defined trials when standard lines are exhausted.
A representative FFPE block or five to ten unstained slides is preferred. For re-testing, a pathology review confirms tumor content above 20 percent before sequencing. Reporting is delivered as a structured PDF with variant classification and therapy mapping. A pathology report accompanying the block speeds triage and reduces repeat requests, which matters when a treatment window is narrow. Specimen rejection criteria follow standard pre-analytical guidelines to protect result reliability.
FFPE blocks travel at ambient temperature with desiccant; frozen tissue requires dry-ice transit. GIVE LIFE TIME International supports overseas labs with labelled packaging and customs-ready documentation, and batches can be consolidated to reduce per-sample freight. Stable reagent kits and validated protocols keep inter-batch consistency predictable for routine procurement. For long-haul routes, thermal packaging is selected by season to avoid summer heat exposure during transit.
Q: Which gastric cancer patients gain the most from a 98-gene panel? A: Those with advanced disease being considered for HER2, FGFR2, or immune-based pathways, especially when histology alone is inconclusive. The panel is most decisive before the first biomarker-directed line.
Q: Can this test replace single-gene HER2 IHC? A: No. It complements IHC by adding copy-number and MSI context, but local HER2 confirmation remains part of standard practice and is still reported separately.
Q: How should overseas buyers handle specimen shipping? A: Use ambient desiccant packaging for FFPE and dry ice for frozen tissue, with customs documentation supplied by the service lab so the block arrives intact.
Gastric cancer is biologically heterogeneous, and outcomes improve when treatment is chosen by tumor biology rather than by stage alone. A 98-gene testing panel gives oncology teams a population-level view of which patients are most likely to respond to HER2, anti-angiogenic, or immune-based regimens. For B2B buyers supplying hospitals and labs, the value of this assay is its ability to split a mixed gastric cancer population into actionable subgroups before therapy begins. In practice, a single histology report cannot predict which gastric tumor will answer to a given pathway, so genomic stratification has become routine in reference centers that manage advanced disease.
The panel combines next-generation sequencing of 98 cancer-relevant genes with microsatellite instability (MSI) and copy-number analysis. Formalin-fixed tumor tissue is extracted, libraries are prepared, and variants are called against a clinical-grade reference. Reportable alterations include HER2 amplification, FGFR2 changes, Claudin 18.2 status, and mismatch-repair deficiency. Each finding is mapped to a therapy or trial option so the clinician receives a decision-ready summary instead of a raw variant list. Bioinformatics annotation follows a curated knowledge base, and ambiguous variants are classified as pathogenic, likely pathogenic, or variant of unknown significance using published guidelines, which keeps reporting defensible.
This testing fits advanced or metastatic gastric and gastro-esophageal junction adenocarcinoma where a targeted or immunotherapy pathway is under consideration. It is most useful for patients who have not yet received a biomarker-directed line, and for cases where standard histology does not explain treatment resistance. Pathology teams also use it to confirm MSI-high status ahead of immune checkpoint therapy, and it supports enrollment into biomarker-defined trials when standard lines are exhausted.
A representative FFPE block or five to ten unstained slides is preferred. For re-testing, a pathology review confirms tumor content above 20 percent before sequencing. Reporting is delivered as a structured PDF with variant classification and therapy mapping. A pathology report accompanying the block speeds triage and reduces repeat requests, which matters when a treatment window is narrow. Specimen rejection criteria follow standard pre-analytical guidelines to protect result reliability.
FFPE blocks travel at ambient temperature with desiccant; frozen tissue requires dry-ice transit. GIVE LIFE TIME International supports overseas labs with labelled packaging and customs-ready documentation, and batches can be consolidated to reduce per-sample freight. Stable reagent kits and validated protocols keep inter-batch consistency predictable for routine procurement. For long-haul routes, thermal packaging is selected by season to avoid summer heat exposure during transit.
Q: Which gastric cancer patients gain the most from a 98-gene panel? A: Those with advanced disease being considered for HER2, FGFR2, or immune-based pathways, especially when histology alone is inconclusive. The panel is most decisive before the first biomarker-directed line.
Q: Can this test replace single-gene HER2 IHC? A: No. It complements IHC by adding copy-number and MSI context, but local HER2 confirmation remains part of standard practice and is still reported separately.
Q: How should overseas buyers handle specimen shipping? A: Use ambient desiccant packaging for FFPE and dry ice for frozen tissue, with customs documentation supplied by the service lab so the block arrives intact.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
